Diadenosines as FHIT-ness instructors

Journal of Cellular Physiology

Volumn 208, Issue 2, 2006, Pages 274-281

  Campiglio, Manuela ^a   Bianchi, Francesca ^a   Andriani, Francesca ^a   Sozzi, Gabriella ^a   Tagliabue, Elda ^a   Ménard, Sylvie ^a   Roz, Luca ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE DERIVATIVE; DIADENOSINE DERIVATIVE; DIADENOSINE TRIPHOSPHATE; FRAGILE HISTIDINE TRIAD PROTEIN; HYDROLASE; UNCLASSIFIED DRUG;

CANCER; CANCER INHIBITION; CELL CYCLE; ENZYME ACTIVITY; GENE INACTIVATION; HUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN HYDROLYSIS; PROTEIN INTERACTION; REVIEW; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR GENE;

ANIMALS; DINUCLEOSIDE PHOSPHATES; GENES, TUMOR SUPPRESSOR; HUMANS; MODELS, BIOLOGICAL; NEOPLASM PROTEINS;

EID: 33745585804     PISSN: 00219541     EISSN: None     Source Type: Journal    
DOI: 10.1002/jcp.20633     Document Type: Review

References (81)

1. Andriani F, Perego P, Carenini N, Sozzi G, Roz L. 2005. Increased sensitivity to cisplatin in non-small lung cancer cell lines after FHIT gene transfer. Neoplasia 8 [Epub ahead of print].
2. Barnes LD, Garrison PN, Siprashvili Z, Guranowski A, Robinson AK, Ingram SW, Croce CM, Ohta M, Huebner K. 1996. Fhit, a putative tumor suppressor in humans, is a dinucleoside 5′, 5‴-P1, P3-triphosphate hydrolase. Biochemistry 35:11529-11535.
3. Baxi MD, Vishwanatha JK. 1995. Uracil DNA-glycosylase/glyceraldehyde-3- phosphate dehydrogenase is an Ap4A binding protein. Biochemistry 34:9700-9707.
4. Baxi MD, McLennan AG, Vishwanatha JK. 1994. Characterization of the HeLa cell DNA polymerase alpha-associated Ap4A binding protein by photoaffinity labeling. Biochemistry 33:14601-14607.
5. Brenner C. 2002. Hint, Fhit, and GalT: Function, structure, evolution, and mechanism of three branches of the histidine triad superfamily of nucleotide hydrolases and transferases. Biochemistry 41:9003-9014.
6. Brenner C, Pace HC, Garrison PN, Robinson AK, Rosier A, Liu XH, Blackburn GM, Croce CM, Huebner K, Barnes LD. 1997. Purification and crystallization of complexes modeling the active state of the fragile histidine triad protein. Protein Eng 10:1461-1463.
7. Brevet A, Chen J, Leveque F, Plateau P, Blanquet S. 1989. In vivo synthesis of adenylylated bis(5′-nucleosidyl) tetraphosphates (Ap4N) by Escherichia coli aminoacyl-tRNA synthetases. Proc Natl Acad Sci USA 86:8275-8279.
8. Campiglio M, Pekarsky Y, Ménard S, Tagliabue E, Pilotti S, Croce CM. 1999. FHIT loss of function in human primary breast cancer correlates with an advantages stage of the disease. Cancer Res 59:3866-3869.
9. Campiglio M, Olgiati C, Fumagalli M, Fidanza V, Croce CM, Ménard S. 2003. Tumor growth protection by Fhit gene in HER2-transgenic mice. 94th Annual Meeting-Proc AACR 44:961.
10. Cavazzoni A, Petronini PG, Galetti M, Roz L, Andriani F, Carbognani P, Rusca M, Fumarola C, Alfieri R, Sozzi G. 2004. Dose-dependent effect of FHIT-inducible expression in Calu-1 lung cancer cell line. Oncogene 23:8439-8446.
11. Chaudhuri AR, Khan IA, Prasad V, Robinson AK, Luduena RF, Barnes LD. 1999. The tumor suppressor protein Fhit. A novel interaction with tubulin. J Biol Chem 274:24378-24382.
12. Chavan AJ, Haley BE, Volkin DB, Marfia KE, Verticelli AM, Bruner MW, Draper JP, Burke CJ, Middaugh CR. 1994. Interaction of nucleotides with acidic fibroblast growth factor (FGF-1). Biochemistry 33:7193-7202.
13. Chen J, Brevet A, Blanquet S, Plateau P. 1998. Control of 5′,5′-dinucleoside triphosphate catabolism by APH1, a Saccharomyces cerevisiae analog of human FHIT. J Bacteriol 180:2345-2349.
14. Claes P, Grobben B, Van Kolen K, Roymans D, Siegers H. 2001. P2Y(AC)(-)-receptor agonists enhance the proliferation of rat C6 glioma cells through activation of the p42/44 mitogen-activated protein kinase. Br J Pharmacol 134:402-408.
15. Draganescu A, Hodawadekar SC, Gee KR, Brenner C. 2000. Fhit-nucleotide specificity probed with novel fluorescent and fluorogenic substrates. J Biol Chem 275:4555-4560.
16. Dumon KR, Ishii H, Fong LY, Zanesi N, Fidanza V, Mancini R, Vecchione A, Baffa R, Trapasso F, During MJ, Huebner K, Croce CM. 2001a. FHIT gene therapy prevents tumor development in Fhit-deficient mice. Proc Natl Acad Sci USA 98:3346-3351.
17. Dumon KR, Ishii H, Vecchione A, Trapasso F, Baldassarre G, Chakrani F, Druck T, Rosato EF, Williams NN, Baffa R, During MJ, Huebner K, Croce CM. 2001b. Fragile histidine triad expression delays tumor development and induces apoptosis in human pancreatic cancer. Cancer Res 61:4827-4836.
18. Fong LY, Fidanza V, Zanesi N, Lock LF, Siracusa LD, Mancini R, Siprashvili Z, Ottey M, Martin SE, Druck T, McCue PA, Croce CM, Huebner K. 2000. Muir-Torre-like syndrome in Fhit-deficient mice. Proc Natl Acad Sci USA 97:4742-4747.
19. Fuge EK, Farr SB. 1993. AppppA-binding protein E89 is the Escherichia coli heat shock protein ClpB. J Bacteriol 175:2321-2326.
20. Fujishita T, Doi Y, Sonoshita M, Hiai H, Oshima M, Huebner K, Croce CM, Taketo MM. 2004. Development of spontaneous tumours and intestinal lesions in Fhit gene knockout mice. Br J Cancer 91:1571-1574.
21. Garrison PN, Robinson AK, Pekarsky Y, Croce CM, Barnes LD. 2005. Phosphorylation of the human Fhit tumor suppressor on tyrosine 114 in Escherichia coli and unexpected steady state kinetics of the phosphorylated forms. Biochemistry 44:6286-6292.
22. Gasmi L, McLennan AG, Edwards SW. 1996. The diadenosine polyphosphates Ap3A and Ap4A and adenosine triphosphate interact with granulocyte-macrophage colony-stimulating factor to delay neutrophil apoptosis: Implications for neutrophil: Platelet interactions during inflammation. Blood 87:3442-3449.
23. Glover TW, Hoge AW, Miller DE, Ascara-Wilke JE, Adam AN, Dagenais SL, Wilke CM, Dierick HA, Beer DG. 1998. The murine Fhit gene is highly similar to its human orthologue and maps to a common fragile site region. Cancer Res 58:3409-3414.
24. Goerlich O, Foeckler R, Holler E. 1982. Mechanism of synthesis of adenosine(5′)tetraphospho(5′)adenosine (AppppA) by aminoacyl-tRNA synthetases. Eur J Biochem 126:135-142.
25. Golebiowski F, Kowara R, Pawelczyk T. 2001. Distribution of Fhit protein in rat tissues and its intracellular localization. Mol Cell Biochem 226:49-55.
26. Golebiowski F, Szulc A, Szutowicz A, Pawelczyk T. 2004. Ubc9-induced inhibition of diadenosine triphosphate hydrolase activity of the putative tumor suppressor protein Fhit. Arch Biochem Biophys 428:160-164.
27. Guranowski A. 2000. Specific and nonspecific enzymes involved in the catabolism of mononucleoside and dinucleoside polyphosphates. Pharmacol Ther 87:117-139.
28. Guranowski A, Galbas M, Hartmann R, Justesen J. 2000. Selective degradation of 2′-adenylated diadenosine tri- and tetraphosphates, Ap(3)A and Ap(4)A, by two specific human dinucleoside polyphosphate hydrolases. Arch Biochem Biophys 373:218-224.
29. Hirano D, Aoki Y, Ogasawara H, Kodama H, Waga I, Sakanaka C, Shimizu T, Nakamura M. 1996. Functional coupling of adenosine A2a receptor to inhibition of the mitogen-activated protein kinase cascade in Chinese hamster ovary cells. Biochem J 316:81-86.
30. Hu B, Han SY, Wang X, Ottey M, Potoczek MB, Dicker A, Huebner K, Wang Y. 2005a. Involvement of the Fhit gene in the ionizing radiation-activated ATR/CHK1 pathway. J Cell Physiol 202:518-523.
31. Hu B, Wang H, Wang X, Lu HR, Huang C, Powell SN, Huebner K, Wang Y. 2005b. Fhit and CHK1 have opposing effects on homologous recombination repair. Cancer Res 65:8613-8616.
32. Ishii H, Dumon KR, Vecchione A, Fong LY, Baffa R, Huebner K, Croce CM. 2001a. Potential cancer therapy with the fragile histidine triad gene: Review of the preclinical studies. JAMA 286:2441-2449.
33. Ishii H, Dumon KR, Vecchione A, Trapasso F, Mimori K, Alder H, Mori M, Sozzi G, Baffa R, Huebner K, Croce CM. 2001b. Effect of adenoviral transduction of the fragile histidine triad gene into esophageal cancer cells. Cancer Res 61:1578-1584.
34. Ishii H, Vecchione A, Fong LY, Zanesi N, Trapasso F, Furukawa Y, Baffa R, Huebner K, Croce CM. 2004. Cancer prevention and therapy in a preclinical mouse model: Impact of FHIT viruses. Curr Gene Ther 4:53-63.
35. Jackson JA, Carlson EC. 1992. Inhibition of bovine retinal microvascular pericyte proliferation in vitro by adenosine. Am J Physiol 263:H634-H640.
36. Ji L, Fang B, Yen N, Fong K, Min JD, Roth JA 1999. Induction of apoptosis and inhibition of tumorigenicity and tumor growth by adenovirus vector-mediated fragile histidine triad (FHIT) gene overexpression. Cancer Res 59:3333-3339.
37. Jovanovic A, Alekseev AE, Terzic A. 1997. Intracellular diadenosine polyphosphates: A novel family of inhibitory ligands of the ATP-sensitive K+ channel. Biochem Pharmacol 54:219-225.
38. Kisselev LL, Wolfson AD. 1994. Aminoacyl-tRNA synthetases from higher eukaryotes. Prog Nucleic Acid Res Mol Biol 48:83-142.
39. Kisselev LL, Justesen J, Wolfson AD, Frolova LY. 1998. Diadenosine oligophosphates (Ap(n)A), a novel class of signalling molecules? FEBS Lett 427:157- 163.
40. Lasso de la Vega MC, Terradez P, Obrador E, Navarro J, Pellicer JA, Estrela JM. 1994. Inhibition of cancer growth and selective glutathione depletion in Ehrlich tumour cells in vivo by extracellular ATP. Biochem J 298:99-105.
41. Maa M-C, Leu T-H, McCarley DJ, Schatzman RC, Parsons SJ. 1995. Potentiation of epidermal growth factor receptor-mediated oncogenesis by c-Src: Implications for the etiology of multiple human cancers. Proc Natl Acad Sci USA 92:6981-6985.
42. Martin F, Pintor J, Rovira JM, Ripoll C, Miras-Portugal MT, Soria B. 1998. Intracellular diadenosine polyphosphates: A novel second messenger in stimulus-secretion coupling. FASEB J 12:1499-1506.
43. McLennan AG. 2000. Dinucleoside polyphosphates-friend or foe? Pharmacol Ther 87:73-89.
44. Merkulova T, Kovaleva G, Kisselev L. 1994. P1,P3-bis(5′-adenosyl) triphosphate (Ap3A) as a substrate and a product of mammalian tryptophanyl-tRNA synthetase. FEBS Lett 350:287-290.
45. Muller S, Hoege C, Pyrowolakis G, Jentsch S. 2001. SUMO, ubiquitin's mysterious cousin. Nat Rev Mol Cell Biol 2:202-210.
46. Nishizaki M, Sasaki J, Fang B, Atkinson EN, Minna JD, Roth JA, Ji L. 2004. Synergistic tumor suppression by coexpression of FHIT and p53 coincides with FHIT-mediated MDM2 inactivation and p53 stabilization in human non-small cell lung cancer cells. Cancer Res 64:5745-5752.
47. Ohta M, Inoue H, Cotticelli MG, Kastury K, Baffa R, Palazzo J, Siprashvili Z, Mori M, Mccue P, Druck T, Croce CM, Huebner K. 1996. The FHIT gene, spanning the chromosome 3p14.2 fragile site acid renal carcinoma-associated t(3;8) breakpoint, is abnormal in digestive tract cancers. Cell 84:587-597.
48. Ottey M, Han SY, Druck T, Barnoski BL, McCorkell KA, Croce CM, Raventos-Suarez C, Fairchild CR, Wang Y, Huebner K. 2004. Fhit-deficient normal and cancer cells are mitomycin C and UVC resistant. Br J Cancer 91:1669-1677.
49. Pace HC, Garrison PN, Robinson AK, Barnes LD, Draganescu A, Rosier A, Blackburn GM, Siprashvili Z, Croce CM, Huebner K, Brenner C. 1998. Genetic, biochemical, and crystallographic characterization of Fhit-substrate complexes as the active signaling form of Fhit. Proc Natl Acad Sci USA 95:5484-5489.
50. Pekarsky Y, Campiglio M, Siprashvili Z, Druck T, Sedkov Y, Tillib S, Draganescu A, Wermuth P, Rothman JH, Huebner K, Buchberg AM, Mazo A, Brenner C, Croce CM. 1998. Nitrilase and Fhit homologs are encoded as fusion proteins in Drosophila melanogaster and Caenorhabditis elegans. Proc Natl Acad Sci USA 95:8744-8749.
51. Pekarsky Y, Zanesi N, Palamarchuk A, Huebner K, Croce CM. 2002. FHIT: From gene discovery to cancer treatment and prevention. Lancet Oncol 3:748-754.
52. Pekarsky Y, Garrison PN, Palamarchuk A, Zanesi N, Aqeilan RI, Huebner K, Barnes LD, Croce CM. 2004. Fhit is a physiological target of the protein kinase Src. Proc Natl Acad Sci USA 101:3775-3779.
53. Pintor J, Diaz-Hernandez M, Gualix J, Gomez-Villafuertes R, Hernando F, Miras-Portugal MT. 2000. Diadenosine polyphosphate receptors. From rat and guinea-pig brain to human nervous system. Pharmacol Ther 87:103-115.
54. Pintor J, Carracedo G, Alonso MC, Bautista A, Peral A. 2002. Presence of diadenosine polyphosphates in human tears. Pflugers Arch 443:432-436.
55. Pintor J, Peral A, Pelaez T, Martin S, Hoyle CH. 2003. Presence of diadenosine polyphosphates in the aqueous humor: Their effect on intraocular pressure. J Pharmacol Exp Ther 304:342-348.
56. Plateau P, Blanquet S. 1982. Zinc-dependent synthesis of various dinucleoside 5′,5‴-P1,P3-Tri- or 5″,5‴-P1,P4- tetraphosphates by Escherichia coli lysyl-tRNA synthetase. Biochemistry 21:5273-5279.
57. Plateau P, Blanquet S. 1994. Dinucleoside oligophosphates in micro-organisms. Adv Microb Physiol 36:81-109.
58. Roz L, Gramegna M, Ishii H, Croce CM, Sozzi G. 2002. Restoration of fragile histidine triad (FHIT) expression induces apoptosis and suppresses tumorigenicity in lung and cervical cancer cell lines. Proc Natl Acad Sci USA 19:3615-3620.
59. Roz L, Andriani F, Ferrario C, Gariboldi M, Alcalay M, Minardi SP, Delia D, Fierotti MA, Sozzi G. 2003. Analysis of FHIT-regulated gene expression patterns using oligonucleotide arrays. 94th Annual Meeting-Proc.AACR, 1206. Ref Type: Abstract.
60. Roz L, Andriani F, Ferreira CG, Giaccone G, Sozzi G. 2004. The apoptotic pathway triggered by the Fhit protein in lung cancer cell lines is not affected by Bcl-2 or Bcl-x(L) overexpression. Oncogene 23:9102-9110.
61. Sard L, Accornero P, Tornielli S, Delia D, Bunone G, Campiglio M, Colombo PM, Gramegna M, Croce CM, Pierotti MA, Sozzi G. 1999. The tumor suppressor gene FHIT is involved in the regulation of apoptosis and in the cell cycle. Proc Natl Acad Sci USA 96:8489-8492.
62. Seeler JS, Dejean A. 2003. Nuclear and unclear functions of SUMO. Nat Rev Mol Cell Biol 4:690-699.
63. Shi Y, Zou M, Farid NR, Paterson MC. 2000. Association of FHIT (fragile histidine triad), a candidate tumour suppressor gene, with the ubiquitin-conjugating enzyme hUBC9. Biochem J 352:443-448.
64. Sillero MA, De Diego A, Osorio H, Sillero A. 2002. Dinucleoside polyphosphates stimulate the primer independent synthesis of poly(A) catalyzed by yeast poly(A) polymerase. Eur J Biochem 269:5323-5329.
65. Siprashvili Z, Sozzi G, Barnes LD, Mccue P, Robinson AK, Eryomin V, Sard L, Tagliabue E, Greco A, Fusetti L, Schwartz G, Pierotti MA, Croce CM, Huebner K. 1997. Replacement of Fhit in cancer cells suppresses tumorigenicity. Proc Natl Acad Sci USA 94:13771-13776.
66. Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SC, Keith DE, Levin WJ, Stuart SG, Udove J, Ullrich A, Press MF. 1989. Studies of the HER-2/neu protooncogene in human breast and ovarian cancer. Science 244:707-712.
67. Sozzi G, Pastorino U, Moiraghi L, Tagliabue E, Pezzella F, Ghirelli C, Tornielli S, Sard L, Huebner K, Pierotti MA, Croce CM, Pilotti S. 1998. Loss of FHIT function in lung cancer and preinvasive bronchial lesions. Cancer Res 58:5032-5337.
68. Stavrou BM. 2003. Diadenosine polyphosphates: Postulated mechanisms mediating the cardiac effects. Curr Med Chem Cardiovasc Hematol Agents 1: 151-169.
69. Stavrou BM, Sheridan DJ, Flores NA. 2001. Contribution of nitric oxide and prostanoids to the cardiac electrophysiological and coronary vasomotor effects of diadenosine polyphosphates. J Pharmacol Exp Ther 298:531-538.
70. Steinmetz M, Janssen AK, Pelster F, Rahn KH, Schlatter E. 2002. Vasoactivity of diadenosine polyphosphates in human small mesenteric resistance arteries. J Pharmacol Exp Ther 302:787-794.
71. Steinmetz M, Gabriels G, Le TV, Piechota HJ, Rahn KH, Schlatter E. 2003. Vasoactivity of diadenosine polyphosphates in human small renal resistance arteries. Nephrol Dial Transplant 18:2496-2504.
72. Trapasso F, Krakowiak A, Cesari R, Arkles J, Yendamuri S, Ishii H, Vecchione A, Kuroki T, Bieganowski P, Pace HC, Huebner K, Croce CM, Brenner C. 2003. Designed FHIT alleles establish that Fhit-induced apoptosis in cancer cells is limited by substrate binding. Proc Natl Acad Sci USA 100:1592-1597.
73. Tseng JE, Khuri F, Kemp B, Liu D, Hong WK, Mao LMD. 1999. Loss of pFhit expression is frequent but not associated with prognosis in stage-I non-small cell lung cancer (NSCLC). AACR Proceedings, 184. Ref Type: Abstract.
74. Vartanian AA. 2003. Gelsolin and plasminogen activator inhibitor-1 are Ap3A-binding proteins. Ital J Biochem 52:9-16.
75. Vartanian A, Prudovsky I, Suzuki H, Dal PI, Kisselev L. 1997. Opposite effects of cell differentiation and apoptosis on Ap3A/Ap4A ratio in human cell cultures. FEBS Lett 415:160-162.
76. Vecchione A, Sevignani C, Giarnieri E, Zanesi N, Ishii H, Cesari R, Fong LY, Gomella LG, Croce CM, Baffa R. 2004. Inactivation of the FHIT gene favors bladder cancer development. Clin Cancer Res 10:7607-7612.
77. Vollmayer P, Clair T, Goding JW, Sano K, Servos J, Zimmermann H. 2003. Hydrolysis of diadenosine polyphosphates by nucleotide pyrophosphatases/ phosphodiesterases. Eur J Biochem 270:2971-2978.
78. Werner NS, Siprashvili Z, Fong LY, Marquitan G, Schroder JK, Bardenheuer W, Seeber S, Huebner K, Schutte J, Opalka B. 2000. Differential susceptibility of renal carcinoma cell lines to tumor suppression by exogenous Fhit expression. Cancer Res 60:2780-2785.
79. Zamecnik PC, Stephenson ML, Janeway CM, Randerath K. 1966. Enzymatic synthesis of diadenosine tetraphosphate and diadenosine triphosphate with a purified lysyl-sRNA synthetase. Biochem Biophys Res Commun 24:91-97.
80. Zanesi N, Fidanza V, Fong LY, Mancini R, Druck T, Valtieri M, Rudiger T, McCue PA, Croce CM, Huebner K. 2001. The tumor spectrum in FHIT-deficient mice. Proc Natl Acad Sci USA 98:10250-10255.
81. Zanesi N, Mancini R, Sevignani C, Vecchione A, Kaou M, Valtieri M, Calin GA, Pekarsky Y, Gnarra JR, Croce CM, Huebner K. 2005. Lung cancer susceptibility in Fhit-deficient mice is increased by Vhl haploinsufficiency. Cancer Res 65:6576-6582.